| Ms Theresa Integral Dy Djama, DPM | |
|
64 Black Rock Ave, Bridgeport, CT 06605-1200 | |
| (203) 278-3210 | |
| Not Available |
| Full Name | Ms Theresa Integral Dy Djama |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 9 Years |
| Location | 64 Black Rock Ave, Bridgeport, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265828818 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 1073 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optimus Health Care Inc | 9335051580 | 62 |
News Archive
Cystic fibrosis is an inherited disorder caused by genetic mutations that disrupt the normal movement of chloride in and out of cells. Among other health problems, cystic fibrosis compromises the lungs' ability to fight infection and breathe efficiently, making it the most lethal genetic disease in the Caucasian population. Patients have an average lifespan of just 30 to 40 years.
Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays. The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.
On Friday September 28th, a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel unanimously voted 19-0 that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health, an important step toward the FDA market approval of this product manufactured by Second Sight Medical Products, Inc.
Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society.
› Verified 8 days ago
| Provider Name | Optimus Health Care Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1669445946 PECOS PAC ID: 9335051580 Enrollment ID: O20031105000254 |
News Archive
Cystic fibrosis is an inherited disorder caused by genetic mutations that disrupt the normal movement of chloride in and out of cells. Among other health problems, cystic fibrosis compromises the lungs' ability to fight infection and breathe efficiently, making it the most lethal genetic disease in the Caucasian population. Patients have an average lifespan of just 30 to 40 years.
Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays. The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.
On Friday September 28th, a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel unanimously voted 19-0 that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health, an important step toward the FDA market approval of this product manufactured by Second Sight Medical Products, Inc.
Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society.
› Verified 8 days ago
| Provider Name | Pedirite Medical Ct Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1316557309 PECOS PAC ID: 2062831191 Enrollment ID: O20200923001502 |
News Archive
Cystic fibrosis is an inherited disorder caused by genetic mutations that disrupt the normal movement of chloride in and out of cells. Among other health problems, cystic fibrosis compromises the lungs' ability to fight infection and breathe efficiently, making it the most lethal genetic disease in the Caucasian population. Patients have an average lifespan of just 30 to 40 years.
Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays. The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.
On Friday September 28th, a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel unanimously voted 19-0 that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health, an important step toward the FDA market approval of this product manufactured by Second Sight Medical Products, Inc.
Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Theresa Integral Dy Djama, DPM 64 Black Rock Ave, Bridgeport, CT 06605-1200 Ph: (203) 579-5000 | Ms Theresa Integral Dy Djama, DPM 64 Black Rock Ave, Bridgeport, CT 06605-1200 Ph: (203) 278-3210 |
News Archive
Cystic fibrosis is an inherited disorder caused by genetic mutations that disrupt the normal movement of chloride in and out of cells. Among other health problems, cystic fibrosis compromises the lungs' ability to fight infection and breathe efficiently, making it the most lethal genetic disease in the Caucasian population. Patients have an average lifespan of just 30 to 40 years.
Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays. The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.
On Friday September 28th, a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel unanimously voted 19-0 that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health, an important step toward the FDA market approval of this product manufactured by Second Sight Medical Products, Inc.
Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society.
› Verified 8 days ago
Howard W Harinstein Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 4695 Main St, Suite 15, Bridgeport, CT 06606 Phone: 203-334-6878 Fax: 203-373-1372 | |
Dr. Tina Marie Chieco-schwartz, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 2320 Main St, Bridgeport, CT 06606 Phone: 203-366-4506 Fax: 203-384-2908 | |
Dr. Robert D. Schwartz, DPM Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 2320 Main St, Bridgeport, CT 06606 Phone: 203-366-4506 Fax: 203-384-2908 | |
Christopher Lovell, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2409 Main St, Bridgeport, CT 06606 Phone: 203-334-6955 | |
St Vincents Multispecialty Group Inc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2409 Main St, Bridgeport, CT 06606 Phone: 203-334-6955 Fax: 203-334-2851 | |
Primed, Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 4699 Main St, Suite 211, Bridgeport, CT 06606 Phone: 203-374-3464 Fax: 203-374-1020 | |
Family Foot & Ankle Specialists Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 2409 Main St, Bridgeport, CT 06606 Phone: 203-334-6955 Fax: 203-334-2851 |